Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Covered by 2 sources from United States. First reported by CNBC ·
How 2 newspapers cover this story
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Moderna’s stock jumps after biotech raises sales outlook
The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.
Coverage details
2 outlets from United States are covering this story: CNBC and MarketWatch. CNBC published it first, on November 6, 2026; the last outlet to join was MarketWatch, less than an hour later.
